Molecular Switch in the Glucocorticoid Receptor: Active and Passive Antagonist Conformations

Journal of Molecular Biology

Volumn 395, Issue 3, 2010, Pages 568-577

  Schoch, Guillaume A ^a   D'Arcy, Brigitte ^a   Stihle, Martine ^a   Burger, Dominique ^a   Bär, Dominik ^a   Benz, Jörg ^a   Thoma, Ralf ^a   Ruf, Armin ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

antagonist; corepressor; crystal structure; mifepristone; nuclear receptor

Indexed keywords

CELL NUCLEUS RECEPTOR; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR; MIFEPRISTONE; NUCLEAR RECEPTOR COREPRESSOR; OXOSTEROID;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENE SWITCHING; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN STRUCTURE;

EID: 73249124826     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.11.011     Document Type: Article

References (39)

1. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable?. Cell 93 (1998) 487-490
2. McKay L.I., and Cidlowski J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr. Rev. 20 (1999) 435-459
3. Mohler M.L., He Y., Wu Z., Hong S.S., and Miller D.D. Non-steroidal glucocorticoid receptor antagonists: the race to replace RU-486 for anti-glucocorticoid therapy. Expert Opin. Ther. Pat. 17 (2007) 59-81
4. Clark R.D. Glucocorticoid receptor antagonists. Curr. Top. Med. Chem. 8 (2008) 813-838
5. Wurtz J.M., Bourguet W., Renaud J.P., Vivat V., Chambon P., Moras D., and Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 3 (1996) 87-94
6. Pratt W.B., Morishima Y., Murphy M., and Harrell M. Chaperoning of glucocorticoid receptors. Handb. Exp. Pharmacol. 172 (2006) 111-138
7. Wagner B.L., Pollio G., Giangrande P., Webster J.C., Breslin M., Mais D.E., et al. The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins. Endocrinology 140 (1999) 1449-1458
8. Link J.T., Sorensen B., Patel J., Grynfarb M., Goos-Nilsson A., Wang J., et al. Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators. J. Med. Chem. 48 (2005) 5295-5304
9. Fang L., Ricketson D., Getubig L., and Darimont B. Unliganded and hormone-bound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain. Proc. Natl Acad. Sci. USA 103 (2006) 18487-18492
10. Schulz M., Eggert M., Baniahmad A., Dostert A., Heinzel T., and Renkawitz R. RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. J. Biol. Chem. 277 (2002) 26238-26243
11. Wang Q., Blackford Jr. J.A., Song L.N., Huang Y., Cho S., and Simons Jr. S.S. Equilibrium interactions of corepressors and coactivators with agonist and antagonist complexes of glucocorticoid receptors. Mol. Endocrinol. 18 (2004) 1376-1395
12. Zhang S., Jonklaas J., and Danielsen M. The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids 72 (2007) 600-608
13. Chasserot-Golaz S., and Beck G. An approach to the mechanism of the potent antiglucocorticoid: 17 beta-hydroxy-11 beta-4-dimethylaminophenyl-17 alpha-propynyl-estra-4,9-dien-3-one. J. Steroid Biochem. 21 (1984) 585-591
14. Gruol D.J., and Altschmied J. Synergistic induction of apoptosis with glucocorticoids and 3′,5′-cyclic adenosine monophosphate reveals agonist activity by RU 486. Mol. Endocrinol. 7 (1993) 104-113
15. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14 (2000) 121-141
16. Burke L.J., and Baniahmad A. Co-repressors 2000. FASEB J. 14 (2000) 1876-1888
17. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110 (2002) 93-105
18. Kauppi B., Jakob C., Farnegardh M., Yang J., Ahola H., Alarcon M., et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 278 (2003) 22748-22754
19. Madauss K.P., Deng S.J., Austin R.J., Lambert M.H., McLay I., Pritchard J., et al. Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J. Med. Chem. 47 (2004) 3381-3387
20. Zhang Z., Olland A.M., Zhu Y., Cohen J., Berrodin T., Chippari S., et al. Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J. Biol. Chem. 280 (2005) 28468-28475
21. Li Y., Suino K., Daugherty J., and Xu H.E. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol. Cell 19 (2005) 367-380
22. Madauss K.P., Grygielko E.T., Deng S.J., Sulpizio A.C., Stanley T.B., Wu C., et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol. Endocrinol. 21 (2007) 1066-1081
23. Suino-Powell K., Xu Y., Zhang C., Tao Y.G., Tolbert W.D., Simons S.S.J., and Xu H.E. Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol. Mol. Cell. Biol. 28 (2008) 1915-1923
24. Biggadike K., Bledsoe R.K., Hassell A.M., Kirk B.E., McLay I.M., Shewchuk L.M., and Stewart E.L. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J. Med. Chem. 51 (2008) 3349-3352
25. Brooun, A., Brodsky, O., Chien, E., Dougan, D. R., Mol, C. D. & Snell, G. (2007). Crystallization of glucocorticoid receptor, Vol. US Patent 7241868.
26. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
27. Frego L., and Davidson W. Conformational changes of the glucocorticoid receptor ligand binding domain induced by ligand and cofactor binding, and the location of cofactor binding sites determined by hydrogen/deuterium exchange mass spectrometry. Protein Sci. 15 (2006) 722-730
28. Kroe R.R., Baker M.A., Brown M.P., Farrow N.A., Gautschi E., Hopkins J.L., et al. Agonist versus antagonist induce distinct thermodynamic modes of co-factor binding to the glucocorticoid receptor. Biophys. Chem. 128 (2007) 156-164
29. Nagy L., Kao H.Y., Love J.D., Li C., Banayo E., Gooch J.T., et al. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 13 (1999) 3209-3216
30. Raaijmakers H.C., Versteegh J.E., and Uitdehaag J.C. The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation. J. Biol. Chem. 284 (2009) 19572-19579
31. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 (2009) 787-790
32. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415 (2002) 813-817
33. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S., et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 9 (2002) 359-364
34. Pantoliano M.W., Petrella E.C., Kwasnoski J.D., Lobanov V.S., Myslik J., Graf E., et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screening 6 (2001) 429-440
35. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 26 (1993) 795-800
36. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., and Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 40 (2007) 658-674
37. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 (2004) 2126-2132
38. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 53 (1997) 240-255
39. Collaborative Computational Project, No. 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 50 (1994) 760-763